Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of an immunoaffinity process for factor IX purification.

J Tharakan1, D Strickland, W Burgess

  • 1American Red Cross, Jerome H. Holland Laboratory for the Biomedical Sciences, Rockville, Md.

Vox Sanguinis
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Habitat and climate influence hybridization among three genetically distinct Canada jay (Perisoreus canadensis) morphotypes in an avian hybrid zone complex.

Heredity·2023
Same author

Adolescent Binge Drinking Is Associated With Accelerated Decline of Gray Matter Volume.

Cerebral cortex (New York, N.Y. : 1991)·2021
Same author

Substance use patterns in 9-10 year olds: Baseline findings from the adolescent brain cognitive development (ABCD) study.

Drug and alcohol dependence·2021
Same author

Baseline brain function in the preadolescents of the ABCD Study.

Nature neuroscience·2021
Same author

Charting a Course for Implementation Research in Oral Health.

JDR clinical and translational research·2019
Same author

Hypomelanosis of ito : a rare neurocutaneous syndrome.

Neurology India·2018
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
Same journal

Abstracts of the 39th International Congress of the ISBT, Kuala Lumpur, Malaysia, 20-24 June 2026.

Vox sanguinis·2026
See all related articles

A new immunoaffinity process effectively purifies Factor IX (FIX) using a monoclonal antibody (MAb). This method ensures high purity and yield, incorporating viral inactivation for a safe and efficient therapeutic product.

Area of Science:

  • Biochemistry
  • Immunology
  • Biotechnology

Background:

  • Factor IX (FIX) is crucial for blood coagulation.
  • Existing purification methods may have limitations in purity and efficiency.
  • Development of highly specific purification techniques is essential for therapeutic applications.

Purpose of the Study:

  • To develop an immunoaffinity purification process for Factor IX (FIX).
  • To ensure high purity and yield of FIX.
  • To incorporate viral inactivation steps into the purification process.

Main Methods:

  • Immunoaffinity chromatography utilizing a monoclonal antibody (MAb) specific to FIX.
  • Initial isolation of vitamin-K-dependent proteins using DEAE-Sephadex.
  • Elution of FIX using citrate or EDTA buffers.

Related Experiment Videos

  • Viral inactivation via solvent/detergent treatment.

    • Main Results:

    • The process achieved high purity FIX with no detectable contaminating proteins via coagulation assays and Western blots.
    • Purity was confirmed by SDS-PAGE and HPLC, with N-terminal sequencing matching FIX.
    • Yields exceeded 95% with no detectable MAb leakage.
    • Triton X-100 was effectively removed to <1 ppm.

    Conclusions:

    • The developed immunoaffinity process is highly effective for purifying Factor IX.
    • The method yields a pure, safe, and efficient FIX product suitable for therapeutic use.
    • The process demonstrates efficient MAb utilization and robust viral inactivation.